81 related articles for article (PubMed ID: 15025518)
1. 90Y and 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent.
Onthank DC; Liu S; Silva PJ; Barrett JA; Harris TD; Robinson SP; Edwards DS
Bioconjug Chem; 2004; 15(2):235-41. PubMed ID: 15025518
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy.
Harris TD; Kalogeropoulos S; Nguyen T; Liu S; Bartis J; Ellars C; Edwards S; Onthank D; Silva P; Yalamanchili P; Robinson S; Lazewatsky J; Barrett J; Bozarth J
Cancer Biother Radiopharm; 2003 Aug; 18(4):627-41. PubMed ID: 14503959
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
Harris TD; Cheesman E; Harris AR; Sachleben R; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Silva P; Robinson S; Lazewatsky J; Rajopadhye M; Barrett J
Bioconjug Chem; 2007; 18(4):1266-79. PubMed ID: 17579472
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents.
Harris TD; Kalogeropoulos S; Nguyen T; Dwyer G; Edwards DS; Liu S; Bartis J; Ellars C; Onthank D; Yalamanchili P; Heminway S; Robinson S; Lazewatsky J; Barrett J
Bioconjug Chem; 2006; 17(5):1294-313. PubMed ID: 16984141
[TBL] [Abstract][Full Text] [Related]
5. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
6. Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138.
Mousa SA; Mohamed S
J Cardiovasc Pharmacol; 2005 Feb; 45(2):109-13. PubMed ID: 15654258
[TBL] [Abstract][Full Text] [Related]
7. Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist.
Liu S; Harris TD; Ellars CE; Edwards DS
Bioconjug Chem; 2003; 14(5):1030-7. PubMed ID: 13129408
[TBL] [Abstract][Full Text] [Related]
8. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Mousa SA; Mohamed S; Wexler EJ; Kerr JS
Anticancer Res; 2005; 25(1A):197-206. PubMed ID: 15816539
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.
Jang BS; Lim E; Hee Park S; Shin IS; Danthi SN; Hwang IS; Le N; Yu S; Xie J; Li KC; Carrasquillo JA; Paik CH
Nucl Med Biol; 2007 May; 34(4):363-70. PubMed ID: 17499725
[TBL] [Abstract][Full Text] [Related]
11. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.
Liu Z; Jia B; Zhao H; Chen X; Wang F
Mol Imaging Biol; 2011 Feb; 13(1):112-20. PubMed ID: 20383594
[TBL] [Abstract][Full Text] [Related]
13. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
Dijkgraaf I; Kruijtzer JA; Frielink C; Corstens FH; Oyen WJ; Liskamp RM; Boerman OC
Int J Cancer; 2007 Feb; 120(3):605-10. PubMed ID: 17096340
[TBL] [Abstract][Full Text] [Related]
14. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.
Dijkgraaf I; Kruijtzer JA; Frielink C; Soede AC; Hilbers HW; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC
Nucl Med Biol; 2006 Nov; 33(8):953-61. PubMed ID: 17127167
[TBL] [Abstract][Full Text] [Related]
16. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
17. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, and X-ray crystal structure of In(DOTA-AA) (AA = p-aminoanilide): a model for 111In-labeled DOTA-biomolecule conjugates.
Liu S; He Z; Hsieh WY; Fanwick PE
Inorg Chem; 2003 Dec; 42(26):8831-7. PubMed ID: 14686864
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
[TBL] [Abstract][Full Text] [Related]
20. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
